论文部分内容阅读
目的:观察多索茶碱辅助治疗慢性喘息性支气管炎(CAB)的临床疗效及不良反应。方法:入选CAB患者160例,随机分为观察组(80例)和对照组(80例),两组均给予常规综合治疗,对照组采用氨茶碱治疗,观察组采用多索茶碱治疗。治疗后比较两组的临床疗效及不良反应发生率。结果:治疗后观察组总有效率为92.50%显著高于对照组81.25%,差异有统计学意义(P<0.05);观察组不良反应总发生率为6.25%显著低于对照的31.25%,差异有统计学意义(P<0.05)。结论:多索茶碱可以提高CAB治疗的临床疗效,且不良反应少,值得临床推广。
Objective: To observe the clinical efficacy and side effects of doxofylline in the treatment of chronic asthmatic bronchitis (CAB). Methods: One hundred and sixty patients with CAB were randomly divided into observation group (80 cases) and control group (80 cases). Both groups were given conventional therapy. The control group was treated with aminophylline. The observation group was treated with doxofylline. After treatment, the clinical efficacy and incidence of adverse reactions in both groups were compared. Results: After treatment, the total effective rate in observation group was 92.50%, which was significantly higher than 81.25% in control group (P <0.05). The total adverse reaction rate in observation group was 6.25%, which was significantly lower than that in control group (31.25% There was statistical significance (P <0.05). Conclusion: Doxofylline can improve the clinical curative effect of CAB with fewer side effects and is worthy of clinical promotion.